Efficacy and safety profile of evolocumab (AMG145), an injectable inhibitor of the proprotein convertase subtilisin/kexin type 9: the available clinical evidence

Author： Cicero Arrigo FG   Tartagni Elisa   Ertek Sibel  

Publisher： Informa Healthcare

ISSN： 1471-2598

Source： Expert Opinion on Biological Therapy, Vol.14, Iss.6, 2014-06, pp. : 863-868

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Quercetin‐3‐glucoside increases low‐density lipoprotein receptor (LDLR) expression, attenuates proprotein convertase subtilisin/kexin 9 (PCSK9) secretion, and stimulates LDL uptake by Huh7 human hepatocytes in culture

By  

FEBS Open Bio, Vol. 4, Iss. 1, 2014-01 ,pp. : 755-762

John Wiley & Sons Inc

Access to resources Recommend Favorite

Highly Regulated Expression of Subtilisin-like Proprotein Convertase PACE4 (SPC4) during Dentinogenesis

By Akamatsu T.   Matsuda Y.   Tsumura K.   Tada J.   Parvin M.N.   Wei W.   Kanamori N.   Hosoi K.  

Biochemical and Biophysical Research Communications, Vol. 272, Iss. 2, 2000-06 ,pp. : 410-415

Elsevier

Access to resources Recommend Favorite

Human Proteinase Inhibitor 9 (PI9) Is a Potent Inhibitor of Subtilisin A

By Dahlen J.R.   Foster D.C.   Kisiel W.  

Biochemical and Biophysical Research Communications, Vol. 238, Iss. 2, 1997-09 ,pp. : 329-333

Elsevier

Access to resources Recommend Favorite

Multibranch and Pseudopeptide Approach for Design of Novel Inhibitors of Subtilisin Kexin Isozyme-1

By  

Protein and Peptide Letters, Vol. 13, Iss. 9, 2006-09 ,pp. : 863-876

Bentham Science Publishers

Access to resources Recommend Favorite

Is there a link between proprotein convertase PC7 activity and human lipid homeostasis?

By  

FEBS Open Bio, Vol. 4, Iss. 1, 2014-01 ,pp. : 741-745

John Wiley & Sons Inc

Access to resources Recommend Favorite